cancer

Biopharma stocks were not immune to the broader market downturn seen for much of 2022. The iShares Biotechnology ETF (NASDAQ: IBB), which is heavily weighted with large-cap biotech companies, has lost 13.2% compared to a steeper 27.8% pullback by the SPDR S&P Biotech (NYSE: XBI). What Happened...

Enveric Biosciences (NASDAQ: ENVB) a neuroscience company developing psychedelics and cannabinoids into mental health medicines, announced a collaboration with the University of Calgary’s Hotchkiss Brain Institute. The parties will work on a clinical trial of EVM-101, a treatment based on...

Tetra Bio-Pharma Inc. (TSX: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development announced on Monday that it produced positive initial clinical data from its ongoing Phase 2 clinical trials of QIXLEEF™ (REBORN©1 and PLENITUDE©), which is...

Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS) have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells. The expanded agreement will include a new CAR target and development in China by Cytovia's joint venture entity, ...

PDS Biotechnology Corporation (NASDAQ: PDSB) has temporarily suspended recruitment in the National Cancer Institute (NCI)-led Phase 2 trial of PDS0101 combo trial in advanced HPV cancers The issue is not specific to the PDS0101 trial and is unrelated to the triple combination's...

Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer-related cannabinoid-based medicine, announced on Monday that it has filed two new provisional patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early...

The FDA has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) investigational new drug (IND) application for NTLA-5001. Related Content: Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate. NTLA-5001 is an autologous T cell...

Small-cap stocks have a history of outperforming large-cap names as they have the potential for rapid growth and have event-driven moves for share prices. A company focused on cancer screening and diagnostic tests has outperformed some of the largest healthcare companies over the last five...

Key takeaways: New Horizon’s first-half revenues jumped more than fourfold, assisted by government early cancer testing drive Stock volatility could owe to frothy valuation, as well as unclear timeline for profitability By Richard Barbaroza New Horizon Health Ltd. (HK: 6606), a Chinese...

The FDA on Friday approved Merck & Co Inc's (NYSE: MRK) belzutifan for patients with the rare disorder known as von Hippel-Lindau (VHL) disease.  VHL is a rare genetic disease that causes tumors and cysts to grow throughout the body. Belzutifan was one of the most...

Document Security Systems Inc's (NYSE: DSS) subsidiary, DSS Biomedical International, Inc., has completed a $1 million equity investment in Vivacitas Oncology, Inc. Vivacitas Oncology focuses on developing new treatment options to treat cancers resistant to currently...

Autolus Therapeutics plc (NASDAQ: AUTL) has granted Moderna Inc (NASDAQ: MRNA) an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus' proprietary binders for up to four immuno-oncology targets. Autolus would be eligible to receive an...

The National Medical Products Administration (NMPA) of China has signed off I-Mab's (NASDAQ: IMAB) IND application to initiate a Phase 2 trial of efineptakin alfa for advanced solid tumors. The trial will evaluate efineptakin alfa in combination with anti-PD-1 antibody for...

Atossa Therapeutics Inc (NASDAQ: ATOS) shares are trading higher Tuesday after retail traders were able to push the stock higher. The stock was trading on above-average volume Tuesday and was trending on social media sites throughout the day such as StockTwits. Atossa Therapeutics was up 13.42...

IBio Inc (NYSE: IBIO) has added three anti-cancer targets to its pipeline of therapeutic candidates.  The Company seeks to change the drug development paradigm with the FastPharming Protein Expression System by reducing the time and cost to move from the initial concept to the...